Latest News and Press Releases

Filing four provisional patent applications...underscores our relentless drive to protect and expand our groundbreaking proenzyme technology

ANN ARBOR, Mich., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Peptinovo Biopharma, an Ann Arbor–based biotechnology company pioneering targeted cancer therapies through its first-of-its-kind proprietary PALM™...

The patent application describes an optimized expression system to produce a world-first fully synthetic recombinant version of PRP

Growing demand for precision medicine and next-generation cancer therapies continues to fuel the global biological therapies market.

GALWAY, IRELAND, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Luminate, a healthcare technology company which helps patients to receive cancer treatments at home, has raised $21 million in an expanded Series A...

Our findings demonstrate that PRP exerts multifaceted effects specifically over the cancer associated fibroblasts (CAFs) population and tumor cells.

The global market for brain tumor therapeutics was valued at $2.5 billion in 2024 and is projected to reach $4.7 billion by the end of 2030.

"Our cells naturally become more mesenchymal over time, so PRP’s ability to potentially reverse this trend is of tremendous scientific interest"

Hawai’i Cancer Care and American Oncology Network Open New Kahului Clinic

These patents represent a significant turning point for Propanc and commercial potential of PRP for treating chronic diseases such as cancer and fibrosis